Orders for Merck & Co's oral antiviral for COVID-19 helped to swell ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE ... of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to ...

Blockbuster drugs rake in at least $1 billion in ... will end at the beginning of August. Sales of Merck's Covid antiviral ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales ... and lower sales of COVID ...